The primary objective of the study was to assess the safety in use of the drug Heparin Sodium, produced by Cristália Laboratory, compared drug Liquemine ®, manufactured by Roche Laboratory, and secondary purpose was to evaluate the non-inferiority clinical testing of the product on the product comparator and pharmacodynamic effect, as evidenced by analyzing the parameters and TTPA Anti-Xa in patients with chronic renal failure in treatment of hemodialysis.

Inclusion Criteria:

• Adults of both sexes, regardless of color or social class
• Age over 18 years with a good clinical medical criteria
• Patients who agreed to participate and signed the Informed Consent
• Insufficient patients in chronic renal dialysis schedule (3 times per week)
• Patients with creatinine clearance <30ml/min
• Patients with indication for anticoagulation during hemodialysis

Exclusion Criteria:

• Patients with sensitivity to heparin sodium;
• Patients with hypersensitivity to benzyl alcohol
• Patients with a history of bleeding or illness that can change the blood coagulation aggravate or terminate the clinical picture, such as tables of gastric ulcer
• Patients with a history of peptic ulcer
• Patients with body mass index greater than 30
• Cancer patients because of the possibility of compromising the function of the variable coagulation
• Patients in period of pregnancy or after delivery
• Patients with genetic abnormality of the clotting system
• Polytraumatized patients
• Patients using glucocorticoids for at least 1 month
• Patients using other anticoagulants
• Patients with high rate of bleeding
• Patients undergoing any surgery performed less than 15 days due to the risk of training of hematoma at the site of surgery
• Hypertension above 140/90 mmHg
• Patients using medications that could affect hemostasis
• Patients using the following medicines: hormonal anti not including Ketorolac; Dextran 40, ticlopidine and clopidogrel, systemic glucocorticoids, thrombolytic agents and anticoagulants and other antiplatelet agents, including antagonists of glycoprotein IIb / IIIa.